about
FGF receptors: cancer biology and therapeuticsModulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectivesDNA methylation profiles in ovarian cancer: implication in diagnosis and therapy (Review)Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer.Promoter hypomethylation of EpCAM-regulated bone morphogenetic protein gene family in recurrent endometrial cancerDecitabine reactivated pathways in platinum resistant ovarian cancer.Frequent SOCS3 and 3OST2 promoter methylation and their epigenetic regulation in endometrial carcinoma.Discovery of chemotherapy-associated ovarian cancer antigens by interrogating memory T cells.Hsa-microRNA-181a is a regulator of a number of cancer genes and a biomarker for endometrial carcinoma in patients: a bioinformatic and clinical study and the therapeutic implication.Ovarian cancer: in search of better marker systems based on DNA repair defectsA potential diagnostic marker for ovarian cancer: Involvement of the histone acetyltransferase, human males absent on the first.Epigenetics and cervical cancer: from pathogenesis to therapy.The role of microRNAs in the pathogenesis of endometrial cancer: a systematic review.Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control.Epigenetic changes as prognostic predictors in endometrial carcinomas.Distinct methylation profile of mucinous ovarian carcinoma reveals susceptibility to proteasome inhibitors.CADM1, MAL and miR124-2 methylation analysis in cervical scrapes to detect cervical and endometrial cancer.
P2860
Q28291186-B008F076-4580-41C9-A470-02480160439FQ30570945-5D7F7DF0-4D43-481F-86FD-BC0FF2E347ADQ33799002-AA50A2A5-22C5-4831-BC06-F9C9FD8913B7Q33827681-17BA73C2-25EE-4012-BC35-6166CC0734B5Q33841409-72D0B857-1455-40B7-A8E9-D1C56A3C253FQ33976957-A2D2C279-2FC4-4395-9EE9-6CBB1188ECE8Q34991225-29D4E312-198C-429C-A6E3-023CD35B950DQ35024484-ED68D870-7F52-4EB4-8B92-E8B637E15686Q35125641-F6536150-19D0-401E-A4BD-5C9B1569B801Q36589947-4D8178A6-303B-4783-9C3F-2A2B9D919101Q37211695-74AF7FDC-0FBE-4D27-B8D9-A8EB87080D51Q38189740-A162CD77-189C-4584-9346-EC1E74F214A4Q38362213-E6EEA597-E6B4-48A4-B899-45889BA81C01Q38923113-87856379-F43F-4C1E-8285-990F1416F3DFQ40462424-C4183896-BB53-4C41-B4C6-28C451A6348CQ49937490-F8BF204C-A42A-4DAD-96A6-E87DED4D6ABDQ53229949-A7F79EE1-5912-43E7-963A-556DE32D53D1
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Role of epigenomics in ovarian and endometrial cancers.
@en
Role of epigenomics in ovarian and endometrial cancers.
@nl
type
label
Role of epigenomics in ovarian and endometrial cancers.
@en
Role of epigenomics in ovarian and endometrial cancers.
@nl
prefLabel
Role of epigenomics in ovarian and endometrial cancers.
@en
Role of epigenomics in ovarian and endometrial cancers.
@nl
P2093
P2860
P356
P1433
P1476
Role of epigenomics in ovarian and endometrial cancers.
@en
P2093
Curtis Balch
Daniela E Matei
Kenneth P Nephew
Tim H-M Huang
P2860
P304
P356
10.2217/EPI.10.19
P577
2010-06-01T00:00:00Z